Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.58 - $1.13 $21,438 - $41,768
-36,963 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$0.73 - $1.81 $1,266 - $3,140
-1,735 Reduced 4.48%
36,963 $37,000
Q4 2021

Feb 11, 2022

BUY
$1.66 - $2.64 $1,005 - $1,599
606 Added 1.59%
38,698 $64,000
Q3 2021

Nov 12, 2021

SELL
$2.58 - $3.36 $2,337 - $3,044
-906 Reduced 2.32%
38,092 $102,000
Q2 2021

Aug 13, 2021

BUY
$2.7 - $3.81 $26,063 - $36,777
9,653 Added 32.89%
38,998 $129,000
Q1 2021

May 07, 2021

BUY
$3.02 - $5.16 $232 - $397
77 Added 0.26%
29,345 $97,000
Q4 2020

Feb 12, 2021

BUY
$2.66 - $4.18 $32,292 - $50,745
12,140 Added 70.88%
29,268 $111,000
Q3 2020

Nov 04, 2020

SELL
$3.01 - $3.88 $1,176 - $1,517
-391 Reduced 2.23%
17,128 $54,000
Q2 2020

Aug 12, 2020

BUY
$2.33 - $4.6 $2,420 - $4,779
1,039 Added 6.3%
17,519 $56,000
Q1 2020

May 04, 2020

SELL
$1.91 - $4.52 $1,818 - $4,303
-952 Reduced 5.46%
16,480 $44,000
Q4 2019

Feb 05, 2020

SELL
$2.57 - $4.08 $375 - $595
-146 Reduced 0.83%
17,432 $71,000
Q3 2019

Nov 08, 2019

SELL
$2.74 - $4.65 $337 - $571
-123 Reduced 0.69%
17,578 $57,000
Q2 2019

Aug 13, 2019

BUY
$2.66 - $6.28 $19,702 - $46,515
7,407 Added 71.95%
17,701 $65,000
Q1 2019

May 06, 2019

SELL
$2.95 - $5.61 $985 - $1,873
-334 Reduced 3.14%
10,294 $35,000
Q4 2018

Feb 13, 2019

SELL
$2.3 - $5.78 $188 - $473
-82 Reduced 0.77%
10,628 $31,000
Q3 2018

Nov 09, 2018

SELL
$5.71 - $7.58 $816 - $1,083
-143 Reduced 1.32%
10,710 $64,000
Q2 2018

Aug 08, 2018

BUY
$6.68 - $11.0 $72,498 - $119,383
10,853 New
10,853 $75,000

Others Institutions Holding MBIO

About MUSTANG BIO, INC.


  • Ticker MBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,222,000
  • Market Cap $22.1M
  • Description
  • Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (...
More about MBIO
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.